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In the last decade the number of
bioscience journals has increased enor-
mously, with many filling specialised niches
reflecting new disciplines and technologies.
The emergence of open-access journals has
revolutionised the publication process,
maximising the availability of research
data. Nevertheless, a wealth of evidence
shows that across many areas, the reporting
of biomedical research is often inadequate,
leading to the view that even if the science is
sound, in many cases the publications
themselves are not ‘‘fit for purpose,’’
meaning that incomplete reporting of
relevant information effectively renders
many publications of limited value as
instruments to inform policy or clinical
and scientific practice [1–21]. A recent
review of clinical research showed that
there is considerable cumulative waste of
financial resources at all stages of the
research process, including as a result of
publications that are unusable due to poor
reporting [22]. It is unlikely that this issue is
confined to clinical research [2–14,16–20].
Failure to describe research methods
and to report results appropriately there-
fore has potential scientific, ethical, and
economic implications for the entire re-
search process and the reputation of those
involved in it. This is particularly true for
animal research, one of the most contro-
versial areas of science. The largest and
most comprehensive review of published
animal research undertaken to date, to our
knowledge, has highlighted serious omis-
sions in the way research using animals is
reported [5]. The survey, commissioned
by the National Centre for the Replace-
ment, Refinement and Reduction of
Animals in Research (NC3Rs), a UK
Government-sponsored scientific organi-
sation, found that only 59% of the 271
randomly chosen articles assessed stated
the hypothesis or objective of the study,
and the number and characteristics of the
animals used (i.e., species/strain, sex, and
age/weight). Most of the papers surveyed
did not report using randomisation (87%)
or blinding (86%) to reduce bias in animal
selection and outcome assessment. Only
70% of the publications that used statisti-
cal methods fully described them and
presented the results with a measure of
precision or variability [5]. These findings
are a cause for concern and are consistent
with reviews of many research areas,
including clinical studies, published in
recent years [2–22].
Good Reporting Is Essential for
Peer Review and to Inform
Future Research
Scrutiny by scientific peers has long
been the mainstay of ‘‘quality control’’ for
the publication process. The way that
experiments are reported, in terms of the
level of detail of methods and the presen-
tation of key results, is crucial to the peer
review process and, indeed, the subse-
quent utility and validity of the knowledge
base that is used to inform future research.
The onus is therefore on the research
community to ensure that their research
articles include all relevant information to
allow in-depth critique, and to avoiding
duplicating studies and performing redun-
dant experiments. Ideally scientific publi-
cations should present sufficient informa-
tion to allow a knowledgeable reader to
understand what was done, why, and how,
and to assess the biological relevance of
the study and the reliability and validity of
the findings. There should also be enough
information to allow the experiment to be
repeated [23]. The problem therefore is
how to ensure that all relevant information
is included in research publications.
Using Reporting Guidelines
Measurably Improves the
Quality of Reporting
Evidence provided by reviews of pub-
lished research suggests that many re-
searchers and peer reviewers would benefit
from guidance about what information
should be provided in a research article.
The CONSORT Statement for rando-
mised controlled clinical trials was one of
the first guidelines developed in response
to this need [24,25]. Since publication, an
increasing number of leading journals
have supported CONSORT as part of
their instructions to authors [26,27]. As a
result, convincing evidence is emerging
that CONSORT improves the quality and
transparency of reports of clinical trials
[28,29].
Following CONSORT, many other
guidelines have been developed—there
are currently more than 90 available for
reporting different types of health re-
search, most of which have been published
in the last ten years (see http://www.
equator-network.org and references
[30,31]). Guidelines have also been devel-
oped to improve the reporting of other
specific bioscience research areas includ-
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ing metabolomics and gene expression
studies [32–37]. Several organisations
support the case for improved reporting
and recommend the use of reporting
guidelines, including the International
Committee of Medical Journal Editors,
the Council of Science Editors, the
Committee on Publication Ethics, and
the Nuffield Council for Bioethics [38–41].
Improving the Reporting of
Animal Experiments—The
ARRIVE Guidelines
Most bioscience journals currently pro-
vide little or no guidance on what
information to report when describing
animal research [42–50]. Our review
found that 4% of the 271 journal articles
assessed did not report the number of
animals used anywhere in the methods or
the results sections [5]. Reporting animal
numbers is essential so that the biological
and statistical significance of the experi-
mental results can be assessed or the data
reanalysed, and is also necessary if the
experimental methods are to be repeated.
Improved reporting of these and other
details will maximise the availability and
utility of the information gained from
every animal and every experiment, pre-
venting unnecessary animal use in the
future. To address this, we led an initiative
to produce guidelines for reporting animal
research. The guidelines, referred to as
ARRIVE (Animals in Research: Report-
ing In Vivo Experiments), have been
developed using the CONSORT State-
ment as their foundation [24,25].
The ARRIVE guidelines consist of a
checklist of 20 items describing the
minimum information that all scientific
publications reporting research using ani-
mals should include, such as the number
and specific characteristics of animals used
(including species, strain, sex, and genetic
background); details of housing and hus-
bandry; and the experimental, statistical,
and analytical methods (including details
of methods used to reduce bias such as
randomisation and blinding). All the items
in the checklist have been included to
promote high-quality, comprehensive re-
porting to allow an accurate critical review
of what was done and what was found.
Consensus and consultation are the
corner-stones of the guideline development
process [51]. To maximise their utility, the
ARRIVE guidelines have been prepared in
consultation with scientists, statisticians,
journal editors, and research funders. We
convened an expert working group, com-
prising researchers and statisticians from a
range of disciplines, and journal editors
from Nature Cell Biology, Science, Laboratory
Animals, and the British Journal of Pharmacol-
ogy (see Acknowledgments). At a one-day
meeting in June 2009, the working group
agreed the scope and broad content of a
draft set of guidelines that were then used as
the basis for a wider consultation with the
scientific community, involving research-
ers, and grant holders and representatives
of the major bioscience funding bodies
including the Medical Research Council,
Wellcome Trust, Biotechnology and Bio-
logical Sciences Research Council, and
The Royal Society (see Table 1). Feedback
on the content and wording of the items
was incorporated into the final version of
the checklist. Further feedback on the
content utility of the guidelines is encour-
aged and sought.
The ARRIVE guidelines (see Table 2)
can be applied to any area of bioscience
research using laboratory animals, and the
inherent principles apply not only to
reporting comparative experiments but
also to other study designs. Laboratory
animal refers to any species of animal
undergoing an experimental procedure in
a research laboratory or formal test
setting. The guidelines are not intended
to be mandatory or absolutely prescriptive,
nor to standardise or formalise the struc-
ture of reporting. Rather they provide a
checklist that can be used to guide authors
preparing manuscripts for publication,
and by those involved in peer review for
quality assurance, to ensure completeness
and transparency.
Improved Reporting Will
Maximise the Output of
Published Research
These guidelines were developed to
maximise the output from research using
animals by optimising the information that
is provided in publications on the design,
conduct, and analysis of the experiments.
The need for such guidelines is further
illustrated by the systematic reviews of
animal research that have been carried out
to assess the efficacy of various drugs and
interventions in animal models [8,9,13,52–
55]. Well-designed and -reported animal
studies are the essential building blocks
from which such a systematic review is
constructed. The reviews have found that,
in many cases, reporting omissions, in
addition to the limitations of the animal
models used in the individual studies
assessed in the review, are a barrier to
reaching any useful conclusion about the
efficacy of the drugs and interventions
being compared [2,3].
Driving improvements in reporting
research using animals will require the
collective efforts of authors, journal edi-
tors, peer reviewers, and funding bodies.
There is no single simple or rapid solution,
but the ARRIVE guidelines provide a
practical resource to aid these improve-
ments. The guidelines will be published in
several leading bioscience research jour-
nals simultaneously [56–60], and publish-
ers have already endorsed the guidelines
by including them in their journal Instruc-
tions to Authors subsequent to publication.
The NC3Rs will continue to work with
journal editors to extend the range of
journals adopting the guidelines, and with
the scientific community to disseminate
the guidelines as widely as possible
(http://www.nc3rs.org.uk/ARRIVE).
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Table 2. Animal Research: Reporting In Vivo experiments: The ARRIVE guidelines.
ITEM RECOMMENDATION
TITLE 1 Provide as accurate and concise a description of the content of the article as possible.
ABSTRACT 2 Provide an accurate summary of the background, research objectives (including details of the species or
strain of animal used), key methods, principal findings, and conclusions of the study.
INTRODUCTION
Background 3 a. Include sufficient scientific background (including relevant references to previous work) to understand
the motivation and context for the study, and explain the experimental approach and rationale.
b. Explain how and why the animal species and model being used can address the scientific objectives
and, where appropriate, the study’s relevance to human biology.
Objectives 4 Clearly describe the primary and any secondary objectives of the study, or specific hypotheses being
tested.
METHODS
Ethical statement 5 Indicate the nature of the ethical review permissions, relevant licences (e.g. Animal [Scientific Procedures]
Act 1986), and national or institutional guidelines for the care and use of animals, that cover the research.
Study design 6 For each experiment, give brief details of the study design, including:
a. The number of experimental and control groups.
b. Any steps taken to minimise the effects of subjective bias when allocating animals to treatment (e.g.,
randomisation procedure) and when assessing results (e.g., if done, describe who was blinded and when).
c. The experimental unit (e.g. a single animal, group, or cage of animals).
A time-line diagram or flow chart can be useful to illustrate how complex study designs were carried out.
Experimental procedures 7 For each experiment and each experimental group, including controls, provide precise details of all
procedures carried out. For example:
a. How (e.g., drug formulation and dose, site and route of administration, anaesthesia and analgesia
used [including monitoring], surgical procedure, method of euthanasia). Provide details of any specialist
equipment used, including supplier(s).
b. When (e.g., time of day).
c. Where (e.g., home cage, laboratory, water maze).
d. Why (e.g., rationale for choice of specific anaesthetic, route of administration, drug dose used).
Experimental animals 8 a. Provide details of the animals used, including species, strain, sex, developmental stage (e.g., mean or
median age plus age range), and weight (e.g., mean or median weight plus weight range).
b. Provide further relevant information such as the source of animals, international strain nomenclature,
genetic modification status (e.g. knock-out or transgenic), genotype, health/immune status, drug- or test-
naı¨ve, previous procedures, etc.
Housing and husbandry 9 Provide details of:
a. Housing (e.g., type of facility, e.g., specific pathogen free (SPF); type of cage or housing; bedding
material; number of cage companions; tank shape and material etc. for fish).
b. Husbandry conditions (e.g., breeding programme, light/dark cycle, temperature, quality of water etc.
for fish, type of food, access to food and water, environmental enrichment).
c. Welfare-related assessments and interventions that were carried out before, during, or after the
experiment.
Sample size 10 a. Specify the total number of animals used in each experiment and the number of animals in each
experimental group.
b. Explain how the number of animals was decided. Provide details of any sample size calculation used.
c. Indicate the number of independent replications of each experiment, if relevant.
Allocating animals to
experimental groups
11 a. Give full details of how animals were allocated to experimental groups, including randomisation or
matching if done.
b. Describe the order in which the animals in the different experimental groups were treated and
assessed.
Experimental outcomes 12 Clearly define the primary and secondary experimental outcomes assessed (e.g., cell death, molecular
markers, behavioural changes).
Statistical methods 13 a. Provide details of the statistical methods used for each analysis.
b. Specify the unit of analysis for each dataset (e.g. single animal, group of animals, single neuron).
c. Describe any methods used to assess whether the data met the assumptions of the statistical
approach.
RESULTS
Baseline data 14 For each experimental group, report relevant characteristics and health status of animals (e.g., weight,
microbiological status, and drug- or test-naı¨ve) before treatment or testing (this information can often be
tabulated).
Numbers analysed 15 a. Report the number of animals in each group included in each analysis. Report absolute numbers (e.g.
10/20, not 50%a).
b. If any animals or data were not included in the analysis, explain why.
Outcomes and estimation 16 Report the results for each analysis carried out, with a measure of precision (e.g., standard error or
confidence interval).
Adverse events 17 a. Give details of all important adverse events in each experimental group.
b. Describe any modifications to the experimental protocols made to reduce adverse events.
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